Varegacestat’s pivotal study reads out imminently.
ApexOnco Front Page
Recent articles
The pivotal Harmoni-GI3 study has started enrolling patients.
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
The company will imminently start its third pivotal trial of PF-08634404.
But the Day One deal is still 29% below where the shares stood at the start of this year.
The company ditches lorigerlimab in prostate cancer.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
